EUVIMEDEUVIMED entdecken
Open Access

Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma

Hay-Ran Jang, Hyun-Jin Kim, Bo-Young Kim, Jae-Hoon Jeong, Jeon-Kyung Kim, Jin Ah Won, Hye Hyun Yoo, Yong Gu Lee, Hyungshin Yim

International Journal of Biological Sciences · 2026

DOI: 10.7150/ijbs.118753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2026. Verfasst von Hay-Ran Jang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan, Republic of Korea. Hauptthemen laut MEDLINE: Spermine, Sorafenib, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), which makes up about 90% of liver cancer, is the third leading cause of cancer-related death. Recent studies suggest that metabolites derived from the gut microbiome may offer new therapeutic opportunities for HCC. In this study, we explored whether microbial metabolites could enhance the effectiveness of sorafenib, a first-line multi-kinase inhibitor used in advanced HCC. Through a screen of a microbiome metabolite library, we identified spermine and sphingosine as potential candidates that boosted anticancer effects of sorafenib in HepG2, Huh7, and SK-Hep-1 cells. These metabolites worked synergistically with sorafenib to suppress tumor growth in cultured HCC cells, patients-derived HCC organoids, and a xenograft mouse model. Mechanistically, spermine triggered cell cycle arrest at the S phase, while sphingosine and sorafenib induced G1 arrest, contributing to an increased sub-G1 population and apoptosis when combined. Notably, sorafenib treatment led to the downregulation of SMOX (a key catabolic enzyme for spermine), as well as SPHK1 and CERS1 (critical enzymes involved in sphingosine metabolism), whose high expression levels are associated with poorer survival outcomes in liver cancer patients according to TCGA data. A 16S rRNA sequencing analysis revealed that combination of sorafenib with spermine or sphingosine alters the gut microbiome, increasing the relative abundance of Faecalibaculum, inversely correlated with tumor sizes in a xenograft mouse model. Therefore, we propose that combining sorafenib with spermine or sphingosine could enhance its anti-HCC effects by promoting apoptosis and reducing the expression of metabolic enzymes. Moreover, Faecalibaculum may serve as a potential microbiome-based prognostic marker for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SpermineSorafenibLiver NeoplasmsCarcinoma, HepatocellularSphingosineGastrointestinal MicrobiomeAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysMetabolic Networks and PathwaysApoptosisMice, Nude

Stichwörter der Autor:innen

liver cancermicrobiome metabolitesorafenibsperminesphingosine

Substanzen

SpermineSorafenibSphingosineAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan, Republic of Korea.
  • School of Pharmacy, Institute of New Drug Development, Jeonbuk National University, Jeonju, Republic of Korea.
  • Pharmacomicrobiomics Research Center, College of Pharmacy, Hanyang University, Ansan, Republic of Korea.

Zitieren

APA

Jang, H. R., Kim, H. J., Kim, B. Y., Jeong, J. H., Kim, J. K., Won, J. A., Yoo, H. H., Lee, Y. G., & Yim, H. (2026). Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.118753

Vancouver

Jang HR, Kim HJ, Kim BY, Jeong JH, Kim JK, Won JA, et al. Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma. International Journal of Biological Sciences. 2026. doi:10.7150/ijbs.118753

BibTeX
@article{Jang2026,
  author = {Jang, Hay-Ran and Kim, Hyun-Jin and Kim, Bo-Young and Jeong, Jae-Hoon and Kim, Jeon-Kyung and Won, Jin Ah and Yoo, Hye Hyun and Lee, Yong Gu and Yim, Hyungshin},
  title = {Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma},
  journal = {International Journal of Biological Sciences},
  year = {2026},
  doi = {10.7150/ijbs.118753}
}
Kostenlos starten →